Australia's most trusted
source of pharma news
Tuesday, 21 January 2025
Posted 10 May, 2024 AM
Kenvue, which became a standalone company last year after cutting ties with Johnson & Johnson, announced this week that it will slash its global workforce by about four per cent bringing in a saving of US$350 million.
The decision coincides with the winding down of Transition Service Agreements with J&J under which the company continued to perform certain services for varying durations for the pharma and medtech giant as part of the spin-off process.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.